12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Human fibrinogen concentrate: Phase III started

CSL's CSL Behring subsidiary began the double-blind, placebo-controlled, international Phase III REPLACE trial to evaluate a single intra-operative infusion of human fibrinogen...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >